ASH 2021 Conference Coverage on VuMedi
D

ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenetapopt & Azacitidine in Patients With TP53 Mutant MDS and Oligoblastic AML

By ASH 2021 Conference Coverage on VuMedi FEATURING David Sallman
By ASH 2021 Conference Coverage on VuMedi FEATURING David Sallman
68 views
January 11, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
12:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian
14:19
Talha Badar

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
13:39
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo
27:28
UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
12:28
Roswell Park Comprehensive Cancer Center

Current Landscape of R/R AML Treatment

Feat. E. Wang
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
02:52
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of …

Feat. M. Amaya